शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

LYKALABSBSELYKA LABS LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 30 Oct, 2026 · 18:21 IST

Q2 revenue rises 28%, profit turns positive; H1 profit Rs 3.42 crore

Revenue growth above 20%Results restatedEBITDA margin expansionResults View source PDFExplain this filing

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-2.0%Reaction day
₹76.60
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.4%-3.4% vs market
Pharmaceuticals peers, median of 174sector+0.2%-2.2% vs sector

On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-2.0+1.4-3.4+0.2-2.2
Next day
-1.3+1.7-3.0+0.6-2.0
2d
-2.0+3.9-5.9+1.6-3.6
3d
+0.6+5.1-4.4+2.3-1.7
4d
+2.6pendingpending+2.2+0.4
5d
—————
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 standalone revenue rose 28.3% year on year to Rs 42.31 crore; profit after tax was Rs 1.32 crore versus a Rs 3.62 crore loss. H1 revenue rose 39.2% to Rs 86.51 crore and profit after tax reached Rs 3.42 crore against a Rs 2.81 crore loss. The auditor's review found no material misstatement. Figures were restated after Lyka Export merged into Lyka Labs. The FY26 comparison includes a Rs 33.24 crore net exceptional charge.

Likely market impact

Strong sales growth and a return to profit support sentiment, though merger-related restatement and the prior-year loss limit clean comparisons.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26
Q2 FY27Q2 FY26Change
Revenue₹44.20 Cr₹36.66 Cr+20.6%
Operating profit₹0.45 Cr−₹5.48 Crturned positive
Profit after tax₹1.27 Cr−₹3.21 Crturned positive
EBITDA margin8.0%-6.9%+14.9 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.